Items Tagged ‘Stages II-III Multiple Myeloma’

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

By

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved […]

View full entry

Tags: blood cancer, bortezomib, CASTOR, CD38, Darzalex, dexamethasone, fda, lenalidomide, Multiple Myeloma, News, POLLUX, Recurrent Multiple Myeloma


July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

By

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that […]

View full entry

Tags: blood cancer, daratumumab, Darxalex, IMid, Multiple Myeloma, News, PI, proteasome inhibitor, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


December 8th, 2014

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma

By

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly diagnosed multiple myeloma, according to the results of a study published in The Lancet Oncology. Multiple myeloma is a cancer of plasma cells. Plasma cells are a special […]

View full entry

Tags: ixazomib, Multiple Myeloma, News, revlimid, Stage I/Smoldering Myeloma Multiple Myeloma, Stages II-III Multiple Myeloma


July 22nd, 2014

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising

By

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance in 31 symptomatic previously untreated transplantation-eligible patients with multiple myeloma under the age of 65. Patients were treated with three cycles of RVD induction followed by autologous stem cell transplantation. Patients then received two RVD […]

View full entry

Tags: Multiple Myeloma, News, Stages II-III Multiple Myeloma


March 10th, 2014

Treanda/Velcade/Dexamethasone Produces High Response Rate in Relapsed/Refractory Multiple Myeloma

By

The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a phase II study published in Blood. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the body’s […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


March 7th, 2014

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma

By

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple myeloma is a cancer of plasma cells (white blood cells that produce antibodies). In 2013, there were an estimated 22,350 new […]

View full entry

Tags: Multiple Myeloma, News, Stage I/Smoldering Myeloma Multiple Myeloma, Stages II-III Multiple Myeloma


March 3rd, 2014

Continuous Revlimid/Lose-Dose Dexamethasone Improves Outcomes in Newly Diagnosed Multiple Myeloma

By

Among people with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation, continuous treatment with Revlimid® (lenalidomide) and low-dose dexamethasone results in better overall survival than standard treatment with melphalan, prednisone, and thalidomide. These results were presented at the 2013 Annual Meeting of the American Society of Hematology. Multiple myeloma is a cancer […]

View full entry

Tags: Multiple Myeloma, News, Stages II-III Multiple Myeloma


February 24th, 2014

Revlimid After Stem Cell Transplantation Delays Progression of Myeloma, but Does Not Improve Overall Survival

By

In a Phase III clinical trial among patients who had undergone stem cell transplantation for multiple myeloma, post-transplant maintenance therapy with Revlimid® (lenalidomide) significantly delayed cancer progression, but did not prolong overall survival. These results were presented at the 2013 Annual Meeting of the American Society of Hematology. Multiple myeloma is a cancer of plasma […]

View full entry

Tags: Multiple Myeloma, News, Stages II-III Multiple Myeloma


February 17th, 2014

Panobinostat Plus Velcade and Dexamethasone Shows Promise in Heavily Pretreated Myeloma

By

The experimental drug panobinostat (LBH-589) in combination with Velcade® (bortezomib) and dexamethasone is effective for heavily pretreated multiple myeloma, according to the final results from a phase 2 clinical trial published in Blood. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


February 10th, 2014

Kyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed Multiple Myeloma

By

The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple myeloma, according to the results of a study published in Blood. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


January 11th, 2013

Zevalin Effective in Relapsed/Refractory Follicular Lymphoma

By

Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Multiple myeloma is a cancer of plasma cells, […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


January 8th, 2013

Pomalidomide Improves Survival in Refractory Multiple Myeloma

By

Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Multiple myeloma is a cancer of plasma cells, […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


January 8th, 2013

Pomalidomide Improves Survival in Refractory Multiple Myeloma

By

Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Multiple myeloma is a cancer of plasma cells, […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


January 3rd, 2013

MLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma

By

The investigational, oral proteasome inhibitor MLN9708, which is a new version of Velcade® (bortezomib)—may be more effective and better tolerated than the Velcade injections, according to data from a mid-stage study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Multiple myeloma is a cancer of plasma cells, which […]

View full entry

Tags: Multiple Myeloma, News, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


September 7th, 2012

Velcade Effective for Induction and Maintenance Treatment of Multiple Myeloma

By

Velcade® (bortezomib) during induction and maintenance treatment improves survival in newly diagnosed stage II or III multiple myeloma, according to the results of a study published in the Journal of Clinical Oncology. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the body’s immune […]

View full entry

Tags: Multiple Myeloma, News, Stages II-III Multiple Myeloma